Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $139,717 - $166,149
-745 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$193.77 - $244.14 $2.32 Million - $2.92 Million
-11,980 Reduced 94.15%
745 $157,000
Q4 2021

Feb 11, 2022

BUY
$223.92 - $287.77 $2.85 Million - $3.66 Million
12,725 New
12,725 $3.05 Million
Q2 2021

Jul 19, 2021

SELL
$259.0 - $414.71 $1.66 Million - $2.65 Million
-6,395 Closed
0 $0
Q1 2021

May 11, 2021

SELL
$242.95 - $284.63 $157,917 - $185,009
-650 Reduced 9.23%
6,395 $1.79 Million
Q4 2020

Feb 11, 2021

SELL
$236.26 - $355.63 $16.3 Million - $24.5 Million
-68,984 Reduced 90.73%
7,045 $1.73 Million
Q3 2020

Nov 13, 2020

BUY
$264.77 - $305.71 $289,923 - $334,752
1,095 Added 1.46%
76,029 $21.6 Million
Q2 2020

Aug 13, 2020

SELL
$258.66 - $342.55 $25.9 Million - $34.3 Million
-100,066 Reduced 57.18%
74,934 $20 Million
Q1 2020

May 12, 2020

BUY
$268.85 - $341.04 $16.1 Million - $20.5 Million
60,000 Added 52.17%
175,000 $55.4 Million
Q4 2019

Feb 11, 2020

BUY
$220.06 - $304.07 $7.99 Million - $11 Million
36,300 Added 46.12%
115,000 $34.1 Million
Q3 2019

Nov 12, 2019

BUY
$217.44 - $243.88 $804,528 - $902,356
3,700 Added 4.93%
78,700 $18.3 Million
Q2 2019

Aug 13, 2019

SELL
$219.29 - $241.72 $25.3 Million - $27.9 Million
-115,600 Reduced 60.65%
75,000 $17.5 Million
Q1 2019

May 14, 2019

BUY
$216.71 - $338.96 $21,671 - $33,896
100 Added 0.05%
190,600 $45.1 Million
Q4 2018

Feb 14, 2019

BUY
$278.5 - $352.75 $25.4 Million - $32.1 Million
91,039 Added 91.53%
190,500 $57.3 Million
Q3 2018

Nov 13, 2018

BUY
$293.51 - $383.83 $29.1 Million - $38.1 Million
99,225 Added 42044.49%
99,461 $35.1 Million
Q2 2018

Aug 01, 2018

SELL
$257.52 - $306.91 $5.09 Million - $6.07 Million
-19,764 Reduced 98.82%
236 $68,000
Q4 2017

Feb 06, 2018

BUY
$307.64 - $344.58 $6.15 Million - $6.89 Million
20,000
20,000 $6.37 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Mufg Securities Emea PLC Portfolio

Follow Mufg Securities Emea PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mufg Securities Emea PLC, based on Form 13F filings with the SEC.

News

Stay updated on Mufg Securities Emea PLC with notifications on news.